Focal small bowel perforation: an adverse effect of early postnatal dexamethasone therapy in extremely low birth weight infants.
OBJECTIVE
We tested the hypothesis that early postnatal dexamethasone (EPD) increases the risk of focal small bowel perforation (FSBP) in extremely low birth weight (ELBW) infants.


METHODS
The techniques of meta-analysis were applied to studies evaluating EPD, which we identified through a systematic literature search. Studies were included if they were randomized, placebo-controlled trials of EPD, enrolled infants with birth weights < or =1000 g, and reported FSBP as an outcome variable. The Breslow-Day test was used to assess for homogeneity and a summary odds ratio was calculated using the Mantel-Haenszel exact method.


RESULTS
Four studies, with a pooled sample of 1383 infants, were included in the primary analysis. The Breslow-Day test showed a p-value of 0.61, indicating homogeneity among the studies. FSBP was significantly higher in EPD treated infants [odds ratio 1.91, 95% confidence interval (CI) 1.21, 3.07; p=0.004].


CONCLUSIONS
EPD increases the risk of FSBP in ELBW infants.
Gordon
P V
PV
Department of Pediatrics, University of North Carolina at Chapel Hill, 27599-7596, USA.
Young
M L
ML
Marshall
D D
DD
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D007416:Intestinal Perforation / Q000139:chemically induced*; D007421:Intestine, Small; D008297:Male; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic
D000893:Anti-Inflammatory Agents; D003907:Dexamethasone